| Literature DB >> 35424265 |
Valeria Scardino1,2, Mariela Bollini3, Claudio N Cavasotto2,4,5.
Abstract
The use of high-throughput docking (HTD) in the drug discovery pipeline is today widely established. In spite of methodological improvements in docking accuracy (pose prediction), scoring power, ranking power, and screening power in HTD remain challenging. In fact, pose prediction is of critical importance in view of the pose-dependent scoring process, since incorrect poses will necessarily decrease the ranking power of scoring functions. The combination of results from different docking programs (consensus scoring) has been shown to improve the performance of HTD. Moreover, it has been also shown that a pose consensus approach might also result in database enrichment. We present a new methodology named Pose/Ranking Consensus (PRC) that combines both pose and ranking consensus approaches, to overcome the limitations of each stand-alone strategy. This approach has been developed using four docking programs (ICM, rDock, Auto Dock 4, and PLANTS; the first one is commercial, the other three are free). We undertook a thorough analysis for the best way of combining pose and rank strategies, and applied the PRC to a wide range of 34 targets sampling different protein families and binding site properties. Our approach exhibits an improved systematic performance in terms of enrichment factor and hit rate with respect to either pose consensus or consensus ranking alone strategies at a lower computational cost, while always ensuring the recovery of a suitable number of ligands. An analysis using four free docking programs (replacing ICM by Auto Dock Vina) displayed comparable results. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35424265 PMCID: PMC8965822 DOI: 10.1039/d1ra05785e
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
The 34 target proteins used in the molecular docking calculations
| Receptor | Receptor code | Receptor | Receptor code |
|---|---|---|---|
| Thymidine kinase | KITH | Tyrosine-protein kinase ABL | ABL1 |
| Phospholipase A2 | PA2GA | Protein-tyrosine phosphatase 1B | PTN1 |
| Coagulation factor VII | FA7 | Inhibitor of apoptosis protein 3 | XIAP |
| Hexokinase type IV | HXK4 | Androgen receptor | ANDR |
| Cyclin-dependent kinase 2 | CDK2 | Renin | RENI |
| Cyclooxygenase-1 | COX1 | Glutamate receptor ionotropic, AMPA 2 | GRIA2 |
| Fatty acid-binding protein 4 | FABP4 | Aldose reductase | ALDR |
| Heat shock protein 90 alpha | HSP90a | Dihydrofolate reductase | DYR |
| Estrogen receptor alpha | ESR1 | Dihydroorotate dehydrogenase | PYRD |
| Neuraminidase | NRAM | 11-Beta-hydroxysteroid dehydrogenase 1 | DHI1 |
| β2 Adrenergic receptor (agonist bound) | ADRB2 | Angiotensin-converting enzyme | ACE |
| HMG-CoA reductase | HMDH | Progesterone receptor | PRGR |
| Dopamine D3 receptor (antagonist bound) | DRD3 | Human immunodeficiency virus type 1 reverse transcriptase | HIVRT |
| Histone deacetylase 2 | HDAC2 | Purine nucleoside phosphorylases | PNPH |
| Leukocyte function associated antigen-1 | LFA1 | Protein kinase C beta | KPCB |
| Leukotriene A4 hydrolase | LKHA4 | Insulin-like growth factor I receptor | IGF1R |
| Urokinase-type plasminogen activator | UROK | Phosphodiesterase 5A | PDE5A |
Average enrichment factor at 1% (EF1) for each individual program calculated on the 34 benchmark targets, and the average fold increase of the ECR method over each program
| Average | ICM | rDock | Auto Dock 4 | PLANTS |
|---|---|---|---|---|
| EF1 | 23.5 | 10.5 | 5.8 | 9.9 |
| Fold increase | 1.4 | 3.4 | 7.4 | 3.2 |
Average value calculated as , where N is the number of targets.
This value does not include XIAP and ANDR, which had EF = 0, and therefore make the average fold increase ≫ 100.
This value does not include these five targets: HXK4, NRAM, XIAP, DYR and PNPH, which had EF = 0, and therefore make the average fold increase ≫ 100.
This value does not include FABP4 and PYRD, which had EF = 0, and therefore make the average fold increase ≫ 100.
EF values for a pose consensus alone strategy of at least two (2 MPs), three (3 MPs) and four matching poses (4 MPs). The best EF for each target is shown in bold
| Receptor | 2 MPs | 3 MPs | 4 MPs |
|---|---|---|---|
| KITH | 1.4 | 2.6 |
|
| PA2GA | 1.6 | 3.4 |
|
| FA7 | 1.6 |
| 3.2 |
| HXK4 | 1.3 | 1.4 |
|
| CDK2 | 1.2 | 1.9 |
|
| COX1 | 1.1 | 1.3 |
|
| FABP4 | 1.2 | 1.5 |
|
| HSP90a | 1.0 | 1.3 |
|
| ESR1 | 1.2 | 1.9 |
|
| NRAM | 1.8 | 4.7 |
|
| ADRB2 | 1.2 |
| 0.4 |
| HMDH | 2.3 | 5.2 |
|
| DRD3 | 1.1 |
| 0.9 |
| HDAC2 | 1.2 |
| 1.8 |
| LFA1 | 0.9 | 1.4 |
|
| LKHA4 | 1.5 |
| 1.8 |
| UROK | 1.5 | 3.8 |
|
| ABL1 | 1.4 | 1.6 |
|
| PTN1 | 1.3 |
| 1.3 |
| XIAP | 1.4 | 4.1 |
|
| ANDR | 1.2 | 1.9 |
|
| Renin | 1.8 | 9.3 |
|
| GRIA2 | 1.4 | 3.5 |
|
| ALDR | 1.2 | 2.0 |
|
| DYR | 1.3 | 1.7 |
|
| PYRD | 1.3 | 2.6 |
|
| DHI1 | 1.1 | 1.7 |
|
| ACE | 1.3 | 5.0 |
|
| PRGR | 1.2 | 1.8 |
|
| HIVRT | 1.4 | 1.8 |
|
| PNPH | 1.2 | 2.3 |
|
| KPCB | 1.3 | 2.6 |
|
| IGF1R | 1.4 |
| 1.6 |
| PDE5A | 1.9 | 4.8 |
|
| Average | 1.4 | 2.7 |
|
EF values and Active/Selected (A/S) molecule rate for option A (2 MPs – top 5%); option B (3 MPs – top 10%); and option C (4 MPs – top 20%). The best option for each target is shown in bold
| Receptor | Option A | Option B | Option C | |||
|---|---|---|---|---|---|---|
| A/S | EF | A/S | EF | A/S | EF | |
| KITH | 24/38 | 14.3 | 3/4 |
| 1/3 | 7.6 |
| PA2GA | 26/48 | 22.8 | 9/10 | 37.9 | 3/3 |
|
| FA7 | 84/107 | 27.5 | 33/35 | 33.1 | 1/1 |
|
| HXK4 | 17/72 |
| 0/10 | 0.0 | 0/2 | 0.0 |
| CDK2 | 23/56 | 12.2 | 17/47 | 10.8 | 11/22 |
|
| COX1 | 11/210 | 1.8 | 11/134 | 2.8 | 9/54 |
|
| FABP4 | 22/65 | 17.3 | 14/30 | 23.8 | 5/7 |
|
| HSP90a | 21/84 |
| 5/23 | 8.8 | 0/5 | 0.0 |
| ESR1 | 44/136 | 17.0 | 30/70 | 22.5 | 19/24 |
|
| NRAM | 20/58 | 10.0 | 10/12 |
| 0/1 | 0.0 |
| ADRB2 | 63/147 |
| 9/38 | 9.5 | 1/10 | 4.0 |
| HMDH | 30/69 | 22.8 | 6/12 | 26.2 | 3/3 |
|
| DRD3 | 11/140 |
| 2/29 | 2.8 | 0/6 | 0.0 |
| HDAC2 | 24/84 | 16.2 | 9/19 |
| 1/5 | 11.3 |
| LFA1 | 15/121 | 7.7 | 11/46 | 14.9 | 3/11 | 17.0 |
| LKHA4 | 36/166 | 12.2 | 12/43 |
| 1/10 | 5.6 |
| UROK | 47/80 | 36.3 | 35/38 |
| 15/19 |
|
| ABL1 | 42/164 | 15.4 | 20/58 |
| 2/18 |
|
| PTN1 | 33/129 | 14.5 | 16/63 |
| 2/21 |
|
| XIAP | 7/13 | 28.2 | 1/2 | 26.2 | 1/1 |
|
| ANDR | 28/172 | 8.8 | 16/45 |
| 7/12 |
|
| Renin | 15/21 | 48.2 | 8/9 | 60.0 | 3/3 |
|
| GRIA2 | 34/129 | 20.0 | 15/37 | 30.8 | 11/12 |
|
| ALDR | 68/188 | 20.8 | 46/97 | 27.3 | 26/48 |
|
| DYR | 39/144 | 20.4 | 12/39 |
| 1/8 |
|
| PYRD | 38/120 | 18.7 | 25/42 |
| 7/14 |
|
| DHI1 | 31/334 | 5.5 | 21/128 |
| 8/60 |
|
| ACE | 30/94 | 19.5 | 7/17 |
| 0/0 |
|
| PRGR | 33/300 | 6.0 | 31/150 | 11.2 | 25/54 |
|
| HIVRT | 47/214 | 12.5 | 17/76 | 12.7 | 5/22 |
|
| PNPH | 44/133 | 22.7 | 29/62 |
| 9/22 | 28.0 |
| KPCB | 47/74 | 41.5 | 25/33 | 49.5 | 15/16 |
|
| IGF1R | 20/43 | 29.7 | 7/13 | 34.3 | 1/1 |
|
| PDE5A | 61/201 | 21.3 | 27/52 | 36.4 | 15/22 |
|
| Average | 33/122 | 18.0 | 16/45 | 23.6 | 6/15 |
|
Number of actives and selected molecules for each target.
Average (A)/average (S).
EF values and Active/Selected (A/S) molecule rate for option D (2 MPs – top 5%; 3 MPs – top 10%; 4 MPs – top 20%) and PRC (option D with an ECR top 1.5% threshold). For the PRC, the hit rate (HR = A/S) is also displayed for a clearer view of the results obtained
| Receptor | Option D | PRC | |||
|---|---|---|---|---|---|
| A/S | EF | A/S | EF | HR | |
| KITH | 15/23 | 14.8 | 13/15 |
| 0.87 |
| PA2GA | 16/30 | 22.4 | 12/16 |
| 0.75 |
| FA7 | 64/73 | 30.7 | 44/45 |
| 0.98 |
| HXK4 | 15/50 | 11.6 | 9/23 |
| 0.39 |
| CDK2 | 14/33 | 12.6 | 11/17 |
| 0.65 |
| COX1 | 11/111 | 3.4 | 8/47 |
| 0.17 |
| FABP4 | 20/37 | 27.6 | 20/25 |
| 0.80 |
| HSP90a | 11/39 | 11.4 | 8/21 |
| 0.38 |
| ESR1 | 33/80 | 21.7 | 33/53 |
| 0.62 |
| NRAM | 14/29 |
| 9/19 | 13.8 | 0.47 |
| ADRB2 | 53/101 | 21.1 | 35/60 |
| 0.58 |
| HMDH | 25/55 | 23.8 | 14/30 |
| 0.47 |
| DRD3 | 7/77 | 3.6 | 6/48 |
| 0.13 |
| HDAC2 | 23/68 | 19.2 | 21/43 |
| 0.49 |
| LFA1 | 9/59 | 9.5 | 8/43 |
| 0.19 |
| LKHA4 | 29/130 | 12.6 | 18/69 |
| 0.26 |
| UROK | 46/70 | 40.5 | 46/50 |
| 0.92 |
| ABL1 | 36/125 | 17.3 | 33/75 |
| 0.44 |
| PTN1 | 31/128 | 13.7 | 24/57 |
| 0.42 |
| XIAP | 4/8 | 26.2 | 3/6 |
| 0.5 |
| ANDR | 12/94 | 6.9 | 10/40 |
| 0.25 |
| Renin | 15/20 | 50.6 | 14/17 |
| 0.82 |
| GRIA2 | 25/83 | 22.9 | 20/52 |
| 0.38 |
| ALDR | 55/135 | 23.5 | 51/81 |
| 0.63 |
| DYR | 34/112 | 22.8 | 24/70 |
| 0.34 |
| PYRD | 31/80 | 22.9 | 30/51 |
| 0.59 |
| DHI1 | 23/245 | 5.6 | 21/136 |
| 0.15 |
| ACE | 27/86 | 19.2 | 22/59 |
| 0.37 |
| PRGR | 36/185 | 10.5 | 30/94 |
| 0.32 |
| HIVRT | 36/169 | 13.5 | 28/97 |
| 0.29 |
| PNPH | 29/87 | 22.8 | 26/51 |
| 0.51 |
| KPCB | 43/65 | 43.2 | 42/51 |
| 0.82 |
| IGF1R | 20/38 | 33.6 | 20/33 |
| 0.61 |
| PDE5A | 46/153 | 21.1 | 41/98 |
| 0.42 |
| Average | 27/85 | 20.0 | 22/50 |
| 0.50 |
Number of actives and selected molecules for each target.
Average (A)/average (S).
Fig. 1PRC pipeline for high-throughput docking.
Comparison of the EF at 1% (EF1) for ECR and the EF of PRC. The fold increase (PRC EF/ECR EF1) is also displayed in the last column
| Receptor | ECR EF1 | PRC EF | Fold increase |
|---|---|---|---|
| KITH | 12.5 |
| 1.58 |
| PA2GA | 25.4 |
| 1.24 |
| FA7 |
| 34.3 | 0.99 |
| HXK4 | 5.5 |
| 2.76 |
| CDK2 | 18.5 |
| 1.04 |
| COX1 | 3.4 |
| 1.71 |
| FABP4 | 40.5 |
| 1.01 |
| HSP90a | 4.9 |
| 3.14 |
| ESR1 |
| 32.8 | 0.93 |
| NRAM | 4.5 |
| 3.07 |
| ADRB2 |
| 23.4 | 0.96 |
| HMDH | 17.1 |
| 1.43 |
| DRD3 | 3.2 |
| 1.56 |
| HDAC2 | 13.6 |
| 2.04 |
| LFA1 | 10.9 |
| 1.06 |
| LKHA4 |
| 14.7 | 0.97 |
| UROK | 44.5 |
| 1.28 |
| ABL1 | 25.3 |
| 1.04 |
| PTN1 |
| 23.9 | 0.81 |
| XIAP | 20.2 |
| 1.30 |
| ANDR | 9.0 |
| 1.50 |
| Renin | 17.4 |
| 3.20 |
| GRIA2 | 19.8 |
| 1.47 |
| ALDR | 33.5 |
| 1.08 |
| DYR |
| 25.8 | 0.99 |
| PYRD | 26.3 |
| 1.32 |
| DHI1 | 8.8 |
| 1.05 |
| ACE | 14.3 |
| 1.59 |
| PRGR | 9.2 |
| 1.88 |
| HIVRT | 15.1 |
| 1.09 |
| PNPH |
| 34.9 | 0.94 |
| KPCB | 45.3 |
| 1.19 |
| IGF1R | 18.3 |
| 2.11 |
| PDE5A | 17.1 |
| 1.71 |
| Average | 20.3 |
| 1.50 |
Average of the fold increase values.
EF values and Active/Selected (A/S) molecule rate for option D (2 MPs – top 5%; 3 MPs – top 10%; 4 MPs – top 20%) and PRC (option D with an ECR top 1.5% threshold) using free docking programs. For the PRC, the hit rate (HR = A/S) is also displayed for a clearer view of the results obtained
| Receptor | Option D | PRC | |||
|---|---|---|---|---|---|
| A/S | EF | A/S | EF | HR | |
| KITH | 3/17 | 4 | 3/9 |
| 0.33 |
| PA2GA | 11/16 | 28.9 | 10/13 |
| 0.77 |
| FA7 | 27/40 | 23.7 | 22/29 |
| 0.76 |
| HXK4 | 2/31 |
| 1/22 | 1.8 | 0.05 |
| CDK2 | 17/34 | 14.9 | 12/22 |
| 0.55 |
| COX1 | 11/236 | 1.6 | 5/91 |
| 0.05 |
| FABP4 | 13/64 | 10.4 | 12/23 |
| 0.52 |
| HSP90a | 2/48 |
| 0/31 | 0 | 0 |
| ESR1 | 36/159 | 11.9 | 31/80 |
| 0.39 |
| NRAM | 4/33 |
| 2/25 | 2.3 | 0.08 |
| ADRB2 | 23/119 | 7.8 | 20/73 |
| 0.27 |
| HMDH | 16/41 |
| 7/21 | 17.5 | 0.33 |
| DRD3 | 9/151 | 2.4 | 6/70 |
| 0.09 |
| HDAC2 | 22/72 | 17.3 | 16/38 |
| 0.42 |
| LFA1 | 10/86 | 7.3 | 9/53 |
| 0.17 |
| LKHA4 | 46/181 | 14.3 | 31/74 |
| 0.42 |
| UROK | 46/89 | 31.9 | 43/62 |
| 0.69 |
| ABL1 | 22/172 | 7.7 | 19/85 |
| 0.22 |
| PTN1 | 28/80 | 19.8 | 23/43 |
| 0.53 |
| XIAP | 2/11 | 9.5 | 2/9 |
| 0.22 |
| ANDR | 14/164 | 4.6 | 13/97 |
| 0.13 |
| Renin | 9/18 | 33.7 | 9/13 |
| 0.69 |
| GRIA2 | 25/95 | 19.9 | 16/51 |
| 0.31 |
| ALDR | 45/187 | 13.9 | 38/90 |
| 0.42 |
| DYR | 24/179 | 10.1 | 20/104 |
| 0.19 |
| PYRD | 28/88 | 18.8 | 24/50 |
| 0.48 |
| DHI1 | 25/317 | 4.7 | 20/169 |
| 0.12 |
| ACE | 16/87 | 11.3 | 11/49 |
| 0.22 |
| PRGR | 36/313 | 6.2 | 21/149 |
| 0.14 |
| HIVRT | 32/269 |
| 14/150 | 5.3 | 0.09 |
| PNPH | 24/90 | 18.3 | 20/52 |
| 0.38 |
| KPCB | 41/92 | 29.1 | 39/56 |
| 0.70 |
| IGF1R | 20/61 | 20.9 | 20/42 |
| 0.48 |
| PDE5A | 44/210 | 14.7 | 39/140 |
| 0.28 |
| Average | 27/140 | 13.4 | 22/78 |
| 0.34 |
Number of actives and selected molecules for each target.
Average (A)/average (S).
Comparison of the EF at 1% (EF1) for ECR and the EF of PRC using free docking programs. The fold increase (PRC EF/ECR EF1) is also displayed in the last column
| Receptor | ECR EF1 | PRC EF | Fold increase |
|---|---|---|---|
| KITH | 2.3 |
| 3.22 |
| PA2GA | 16.7 |
| 1.94 |
| FA7 | 24.1 |
| 1.1 |
| HXK4 | 0.8 |
| 2.23 |
| CDK2 | 12.8 |
| 1.27 |
| COX1 | 1 |
| 1.95 |
| FABP4 | 19.4 |
| 1.38 |
| HSP90a | 0 |
| 1 |
| ESR1 |
| 20.4 | 0.85 |
| NRAM | 0.5 |
| 5.12 |
| ADRB2 | 10.8 |
| 1.03 |
| HMDH | 7.6 |
| 2.30 |
| DRD3 | 3.1 |
| 1.11 |
| HDAC2 | 16.3 |
| 1.46 |
| LFA1 |
| 10.6 | 0.86 |
| LKHA4 | 18.2 |
| 1.30 |
| UROK | 30.9 |
| 1.39 |
| ABL1 |
| 13.4 | 0.74 |
| PTN1 |
| 30.3 | 0.91 |
| XIAP | 6.1 |
| 1.92 |
| ANDR |
| 7.3 | 0.70 |
| Renin | 12.5 |
| 3.74 |
| GRIA2 | 14.7 |
| 1.62 |
| ALDR |
| 24.3 | 0.96 |
| DYR | 10.4 |
| 1.39 |
| PYRD | 20.0 |
| 1.42 |
| DHI1 | 6.1 |
| 1.16 |
| ACE | 5.0 |
| 2.74 |
| PRGR | 4.1 |
| 1.85 |
| HIVRT | 5.3 |
| 1 |
| PNPH | 25.4 |
| 1.04 |
| KPCB | 37.9 |
| 1.20 |
| IGF1R | 17.6 |
| 1.73 |
| PDE5A | 12.9 |
| 1.51 |
| Average | 13.7 |
| 1.62 |
Average of the fold increase values.